Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in USD (TTM)219.39m
- Net income in USD-491.98m
- Incorporated1998
- Employees464.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.51bn | 610.00 | -- | 5.41 | 280.94 | 3.09 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Twist Bioscience Corp | 277.49m | -192.14m | 2.52bn | 919.00 | -- | 4.49 | -- | 9.06 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Avidity Biosciences Inc | 10.87m | -228.68m | 2.59bn | 253.00 | -- | 3.12 | -- | 238.40 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
TG Therapeutics Inc | 289.33m | 41.20m | 2.61bn | 284.00 | 76.74 | 16.33 | 63.21 | 9.04 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Merus NV | 38.34m | -149.65m | 2.65bn | 172.00 | -- | 7.58 | -- | 69.07 | -2.72 | -2.72 | 0.7031 | 5.95 | 0.0917 | -- | 1.21 | 222,889.50 | -35.78 | -29.35 | -43.82 | -35.36 | -- | -- | -390.36 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
Denali Therapeutics Inc | 295.39m | -137.25m | 2.66bn | 375.00 | -- | 1.83 | -- | 9.01 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.68bn | 50.00 | -- | 4.86 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Neogen Corp | 929.24m | 1.57m | 2.69bn | 2.64k | 1,724.00 | 0.8558 | 22.84 | 2.90 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Janux Therapeutics Inc | 7.29m | -55.59m | 2.69bn | 64.00 | -- | 4.11 | -- | 369.58 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.71bn | 160.00 | -- | 3.23 | -- | 445.70 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Morphosys Ag (ADR) | 219.39m | -491.98m | 2.72bn | 464.00 | -- | -- | -- | 12.38 | -3.38 | -3.41 | 1.56 | -1.87 | 0.1002 | 1.86 | 4.58 | 418,687.80 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 2.77bn | 352.00 | 24.88 | 5.05 | 23.27 | 5.29 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Hims & Hers Health Inc | 959.40m | -2.35m | 2.78bn | 1.05k | -- | 8.04 | 344.81 | 2.89 | -0.016 | -0.016 | 4.46 | 1.61 | 2.33 | 6.68 | -- | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | -- | -- | 65.49 | -- | 64.15 | -- | -- | -- |
Amicus Therapeutics, Inc. | 423.49m | -147.07m | 2.81bn | 517.00 | -- | 21.48 | -- | 6.63 | -0.4931 | -0.4931 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Arcellx Inc | 110.32m | -70.69m | 2.81bn | 130.00 | -- | 5.68 | -- | 25.47 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Azenta Inc | 651.76m | -152.26m | 2.87bn | 3.50k | -- | 1.29 | -- | 4.40 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.77 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | -- | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
Holder | Shares | % Held |
---|---|---|
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 6.43m | 4.27% |
Kynam Capital Management LPas of 31 Dec 2023 | 4.23m | 2.81% |
Point72 Asset Management LPas of 31 Dec 2023 | 3.80m | 2.52% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.71m | 1.80% |
Logos Global Management LPas of 31 Dec 2023 | 1.48m | 0.98% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 818.46k | 0.54% |
TD Asset Management, Inc.as of 31 Dec 2023 | 361.14k | 0.24% |
Millennium Management LLCas of 31 Dec 2023 | 329.90k | 0.22% |
Marshall Wace LLPas of 31 Dec 2023 | 326.09k | 0.22% |
Susquehanna Financial Group LLLPas of 31 Dec 2023 | 316.21k | 0.21% |